newsfilter
← Earnings
Earnings Releases·

Castle Biosciences — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue rose 24% year-over-year to $102.9 million, while full-year 2026 revenue guidance was raised to $385–395 million from the previous $365–375 million range.
  • The company maintained its outlook to achieve positive adjusted EBITDA for Q4 2026, the full year 2026, and the full year 2027, despite a Q3 net loss of $4.1 million compared to $0.5 million in Q3 2025.
  • Core revenue drivers (DecisionDx-Melanoma and TissueCypher) saw a 22% increase in test report volume in Q3, led by a 47% surge in TissueCypher, partially offset by declines in DecisionDx-SCC and MyPath Melanoma due to Medicare coverage changes and portfolio re-focus.
  • Strategic initiatives included the launch of new tests AdvanceAD-Tx and Esopredict, the opening of a new 55,000-square-foot facility in Scottsdale, Arizona, and a $0.6 million additional order from SciBase for portable devices.
Company
CASTLE BIOSCIENCES INC
Sector
Healthcare
Industry
Diagnostics & Research